Published ahead of print on November 19, 2004, doi:10.1164/rccm.200404-446OC
Am. J. Respir. Crit. Care Med., Volume 171, Number 4, February 2005, 354-360
A more recent version of this article appeared on February 15, 2005
Submitted on April 2, 2004
Accepted on November 15, 2004
Effects of Carbon Monoxide Inhalation during Experimental Endotoxemia in Humans
Florian B Mayr1, Alexander Spiel1, Judith Leitner1, Claudia Marsik2, Peter Germann3, Roman Ullrich3, Oswald Wagner2, and Bernd Jilma1*
1 Department of Clinical Pharmacology, Medical University Vienna, Vienna, Austria,
2 Department of Medical and Chemical Laboratory Diagnostics, Medical University Vienna, Vienna, Austria,
3 Department of Anesthesiology and General Critical Care Medicine, Medical University Vienna, Vienna, Austria
* To whom correspondence should be addressed. E-mail: Bernd.Jilma{at}meduniwien.ac.at.
Recent data show that carbon monoxide (CO) exerts direct anti-inflammatory effects in vitro and in vivo after lipopolysaccharide (LPS) challenge in a mouse model. We hypothesized that CO may act as an anti-inflammatory agent in human endotoxemia. The aim of this trial was to study the effects of CO inhalation on cytokine production during experimental human endotoxemia. The main study was randomized, double-blinded, placebo-controlled two-way crossover in healthy volunteers. Each volunteer inhaled synthetic air (as placebo) and 500 ppm CO for 1 hour in random order with a washout period of 6 weeks and received a 2 ng/kg intravenous bolus of LPS after inhalation. HbCO levels were assessed as a safety parameter. CO inhalation increased HbCO levels from 1.2% [95%CI: 1.0-1.4%] to peak values of 7.0 [CI:6.5-7.7%]. LPS infusion transiently increased plasma concentrations of TNF , IL-6 (~150-fold increases), IL-8 as well as IL-1 + mRNA levels (~200-fold increase). These LPS-induced changes were not influenced by CO inhalation. Inhalation of 500 ppm CO for 1 hour had no anti-inflammatory effects in a systemic inflammation model in humans as 250 ppm for 1 hour did in rodents.
Key words: CO, endotoxin, TNF, HbCO
This article has been cited by other articles:

|
 |

|
 |
 
L. Wang, J.-Y. S. Lee, J. H. Kwak, Y. He, S. I. Kim, and M. E. Choi
Protective effects of low-dose carbon monoxide against renal fibrosis induced by unilateral ureteral obstruction
Am J Physiol Renal Physiol,
March 1, 2008;
294(3):
F508 - F517.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Sauermann, C. Marsik, I. Steiner, K. Seir, T. Cvitko, M. Zeitlinger, O. Wagner, and C. Joukhadar
Immunomodulatory Effects of Fosfomycin in Experimental Human Endotoxemia
Antimicrob. Agents Chemother.,
May 1, 2007;
51(5):
1879 - 1881.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. W. Ryter, D. Morse, and A. M. K. Choi
Carbon Monoxide and Bilirubin: Potential Therapies for Pulmonary/Vascular Injury and Disease
Am. J. Respir. Cell Mol. Biol.,
February 1, 2007;
36(2):
175 - 182.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. B. Milbrandt, A. Ishizaka, and D. C. Angus
Update in critical care 2005.
Am. J. Respir. Crit. Care Med.,
April 15, 2006;
173(8):
833 - 841.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. B. Hampson, L. K. Weaver, and C. A. Piantadosi
"Low-Level" Carbon Monoxide Administration May Carry Risk
Am. J. Respir. Crit. Care Med.,
September 15, 2005;
172(6):
784 - 784.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Mayr, M. Bilban, and B. Jilma
"Low-Level" Carbon Monoxide Administration May Carry Risk
Am. J. Respir. Crit. Care Med.,
September 15, 2005;
172(6):
784 - 785.
[Full Text]
[PDF]
|
 |
|
Copyright © 2004 American Thoracic Society
|
|
|